In a RegMedNet post today (March 9, 2016), Asymmetrex explains that, although much attention is given to molecular genetics advances in the efficiency and integrity of new technologies for gene therapy, failure to count tissue stem cells is likely to limit future treatment success. Sufficient genetic engineering and transplantation of targeted tissue stem cells, like blood hematopoietic stem cells, are crucial for effective gene therapy. Genetic engineering and gene-editing of rare stem cells face significant competition from abundant committed progenitor cells that can only give short-term treatment. So, the desired long-term treatment depends heavily on stem cell number that is currently an unknown in gene replacement and gene-editing clinical trials. In addition to today’s post, Asymmetrex’s founder and director, James L. Sherley, will give a presentation at 4:30 pm to relate how Asymmetrex’s new AlphaSTEM technology for counting adult tissue stem cells can address this important unmet need. The presentation is an invited talk at the Clinical Trials Supply New England 2016 conference taking place in the Revere Hotel in downtown Boston.
Related Posts
Recent Posts
- Asymmetrex®’s Kinetic Stem Cell (KSC) Counting Technology is Featured in the Parent’s Guide to Cord Blood Foundation® June Newsletter
- Asymmetrex® Presents New Developments in its Rapid Stem Cell Counting Technology at the ARMI|BioFabUSA Meeting in the Millyard on Regenerative Medicine Biomanufacturing
- Asymmetrex® CEO Publishes New Book on Missing Elements of U.S. COVID Science
- Asymmetrex Issued U.S. Trademark Registration for Business Name
- Asymmetrex Discusses Stem Cell-Specific Dosing in Veterinary Medicine with Tech Company News
Tags
- Adult Stem Cells
- Announcements
- Asymmetrex News
- Biotechnology
- Immortality and Stem Cells
- Industry News
- Interview
- Kinetic Stem Cell Counting
- Online Workshop
- Regenerative Medicine
- Reports
- Stem Cell Counting
- Stem Cell Information
- Stem Cell Injections
- Stem Cell Medicine
- Stem Cell Research
- Stem Cell Technology
- Stem Cell Toxicology
- Webinar
Leave a Reply